EMEA-001672-PIP01-14

Key facts

Invented name
  • Copalia
  • Zostavax
Active substance
varicella-zoster virus (live, attenuated)
Therapeutic area
Vaccines
Decision number
P/0309/2014
PIP number
EMEA-001672-PIP01-14
Pharmaceutical form(s)
Powder and solvent for suspension for injection
Condition(s) / indication(s)
Prevention of Varicella-Zoster-Virus reactivation
Route(s) of administration
  • Subcutaneous use
  • Intramuscular use
Contact for public enquiries
Sanofi Pasteur MSD SNC 
France 
E-mail: cbesnard@spmsd.com 
Tel. +33 437284723 
Fax +1 2673056450 / +1 7325944950
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating